Pluristem Therapeutics Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Pluristem Therapeutics Inc. on June 25, 2015. The filing discloses the entry into material definitive agreements regarding a registered direct public offering of the Company's securities.
Key Financial Metrics and Transaction Details
- Gross Proceeds: Approximately $17,000,000 (before deducting fees and expenses).
- Securities Issued: 6,800,000 shares of Common Stock and Warrants to purchase up to 4,080,000 shares.
- Offering Price: $2.50 per Unit (one share plus one warrant).
- Warrant Terms: Exercise price of $2.85; exercisable immediately upon closing for a period of 5 years.
- Placement Agent Fees: Maxim Group LLC to receive up to 6% of gross proceeds plus an expense allowance of up to $40,000.
- Expected Closing Date: On or about June 30, 2015.
The filing does not provide specific data on revenue, profit, cash flow, margins, or existing debt levels as this is a transactional report rather than a periodic financial statement.
Material Changes and Outlook
The primary material change is the agreement to raise capital through the sale of Units to institutional investors. The transaction is subject to customary closing conditions. Management commentary is limited to the terms of the offering and standard forward-looking statement disclaimers regarding the uncertainty of the closing date and other contingencies.
Investor Verification Checklist
- Verify the final closing of the offering and the actual net proceeds received after deducting the 6% placement fee and other expenses.
- Confirm the exact number of shares and warrants issued upon closing.
- Review the Company's subsequent filings for any updates on the use of proceeds.
- Monitor the Company's cash position and burn rate to assess the runway provided by the $17 million gross proceeds.